Aristotle University Of Thessaloniki (AUTH)
Επίδραση της ροσουβαστατίνης στην επούλωση του εγκαυματικού τραύματος: πειραματική μελέτη σε επίμυες
Abstract
dc:descriptionSummary“Effect of Rosuvastatin on Burn Wound Healing: An Experimental Study in Rats” Alexandra Marneri Aristotle University of Thessaloniki 5th Department of Surgery Ippokratio General Hospital Statins are widely recognized for their lipid-lowering capabilities; however, they also possess diverse pleiotropic effects, including anti-inflammatory, immunomodulatory, antimicrobial, antioxidative, and pro-angiogenic properties, which collectively facilitate wound healing. Rosuvastatin, a synthetic hydrophilic statin, has recently been identified as a potential agent to enhance burn wound repair by promoting angiogenesis and expediting tissue regeneration. Its hydrophilic characteristics, extended half-life, and heightened hepatoselectivity relative to other statins are hypothesized to underlie its superior efficacy in burn recovery, as indicated by preliminary findings. Nonetheless, the existing evidence remains limited, underscoring the need for additional experimental investigations and clinical validation.This study aims to examine the effects of rosuvastatin on the burn wound healing process and to elucidate its underlying mechanisms of action in an experimental rat model. A total of ninety male Wistar Albino rats, aged between 12 and 16 weeks, were randomly allocated into three groups of thirty animals each: study, placebo, and control. A partial-thickness burn injury was induced on the dorsal region by applying a stainless steel sealer heated to 85°C for 10 seconds. On the first day post-burn, the eschar was debrided, and topical treatments were administered as follows: rosuvastatin cream for the study group, normal saline for the control group, and Eucerin cream for the placebo group. Subsequently, wounds were covered with sterile dressings. Each group was subdivided into three subgroups of ten rats, corresponding to sacrifice time points at days 3, 6, and 9 post-treatment. Evaluations included quantification of inflammatory markers (IL-1β, IL-6, TNF-α, and CRP), microbial cultures from the burn surface, digital photographic assessment of wound size, and histopathological analysis. Using the third-day values from the control group as baseline, the study group demonstrated statistically significant decreases in serum CRP (5.75–10.30–16.15 vs. 21.40–4.87–9.69, p < 0.01), TNF-α (11.02–21.25–28.21 vs. 35.29–7.83–12.51, p < 0.01), and IL-1β (6.19–10.28–14.41 vs. 17.83–3.72–6.93, p < 0.01), and IL-6 levels (9.71–20.88–29.84 vs. 40.24–5.75–14.37, p < 0.01) as well as a significant reduction in burn wound size (30.52–83.00–135.84 vs. 235.17–31.47–73.62, p < 0.01) across the later sacrifice days. These findings clearly demonstrate a distinct difference in the inflammatory response between the groups during the follow-up period. The study group showed significant and gradual decreases in the levels of the inflammatory markers CRP, TNF-α, IL-1β, and IL-6. This reduction in inflammation correlated with a gradual decrease in burn wound size in the study group (30.52–82.99–133.84 vs. 235.17–31.47–71.61, p < 0.01), indicating a more effective therapeutic response to rosuvastatin. Rosuvastatin administration was associated with enhanced neovascularization (p = 0.012) and a fibroblastic response (p = 0.023), processes critical for the organization of granulation tissue and the promotion of healing. The presence of coagulative necrosis and hemorrhages was less pronounced in treated animals (p < 0.001), suggesting that rosuvastatin has a protective effect on the wound microenvironment. The combination of the above findings demonstrates that rosuvastatin does not act unidimensionally; rather, it affects both the inflammatory and reparative phases of healing, achieving a better balance between the two. The administration of rosuvastatin was found to attenuate inflammatory responses by reducing the levels of pro-inflammatory mediators such as interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), while concurrently enhancing angiogenesis, fibroblastic activity, and the microenvironment. These combined effects contribute to improved wound repair and demonstrate a favorable impact on the healing of burn injuries. The administration of rosuvastatin was safe in this experimental model, with no adverse effects or mortality observed. Nevertheless, further preclinical and clinical research is warranted to fully assess the therapeutic potential of rosuvastatin in burn treatment.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Marneri, Alexandra
- Μαρνέρη, Αλεξάνδρα
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60412